Do current clinical trials in cystic fibrosis match the priorities of patients and clinicans? A systematic review

I. S. Kalaitzis; N. J. Rowbotham; S. J. Smith; A. R. Smyth

doi:10.1016/j.jcf.2019.06.005

Do current clinical trials in cystic fibrosis match the priorities of patients and clinicans? A systematic review

I. S. Kalaitzis
, N. J. Rowbotham^*
, S. J. Smith
, A. R. Smyth

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

There are many uncertainties regarding Cystic Fibrosis (CF) treatment. Recently, the first James Lind Alliance (JLA) Priority Setting Partnership (PSP) in CF was completed, bringing clinicians, patients and carers together to identify the Top 10 research priorities. Here we investigate how well the current clinical trials landscape reflects these priorities. Trials in CF were identified through searches of research databases (Pubmed, ANZCTR, EU clinical trials register, ClinicalTrials.gov and ISRCTN). Trials meeting inclusion criteria of registered intervention studies in CF published between 01.012016 and 11.09.2017 were matched to the Top 10 priorities. We identified 259 trials, with 193 fulfilling the inclusion criteria. Only 63 (33%) of these matched one or more of the JLA priorities showing that current clinical trials poorly reflect the JLA Top 10. By increasing awareness of the Top 10 priorities, it is hoped that this will fuel future research in areas important to the CF community.

Original language	English
Pages (from-to)	26-33
Number of pages	8
Journal	Journal of Cystic Fibrosis
Volume	19
Issue number	1
DOIs	https://doi.org/10.1016/j.jcf.2019.06.005
Publication status	Published - 27 Jan 2020
Externally published	Yes

Bibliographical note

Funding Information:
NJR has given lectures at meetings sponsored by TEVA. AS has provided consultancy for Vertex and holds a current unrestricted research grant from Vertex. He has taken part in clinical trials sponsored by Vertex, Raptor and Insmed. He has given lectures at meetings sponsored by Teva and Vertex.

Publisher Copyright:
© 2019 European Cystic Fibrosis Society

Keywords

Clinical trial
Cystic fibrosis
Research priority

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.jcf.2019.06.005Licence: Unspecified

Cite this

@article{2564fb9a73fe416887b9de187c1c1e0c,

title = "Do current clinical trials in cystic fibrosis match the priorities of patients and clinicans? A systematic review",

abstract = "There are many uncertainties regarding Cystic Fibrosis (CF) treatment. Recently, the first James Lind Alliance (JLA) Priority Setting Partnership (PSP) in CF was completed, bringing clinicians, patients and carers together to identify the Top 10 research priorities. Here we investigate how well the current clinical trials landscape reflects these priorities. Trials in CF were identified through searches of research databases (Pubmed, ANZCTR, EU clinical trials register, ClinicalTrials.gov and ISRCTN). Trials meeting inclusion criteria of registered intervention studies in CF published between 01.012016 and 11.09.2017 were matched to the Top 10 priorities. We identified 259 trials, with 193 fulfilling the inclusion criteria. Only 63 (33\%) of these matched one or more of the JLA priorities showing that current clinical trials poorly reflect the JLA Top 10. By increasing awareness of the Top 10 priorities, it is hoped that this will fuel future research in areas important to the CF community.",

keywords = "Clinical trial, Cystic fibrosis, Research priority",

author = "Kalaitzis, \{I. S.\} and Rowbotham, \{N. J.\} and Smith, \{S. J.\} and Smyth, \{A. R.\}",

note = "Funding Information: NJR has given lectures at meetings sponsored by TEVA. AS has provided consultancy for Vertex and holds a current unrestricted research grant from Vertex. He has taken part in clinical trials sponsored by Vertex, Raptor and Insmed. He has given lectures at meetings sponsored by Teva and Vertex. Publisher Copyright: {\textcopyright} 2019 European Cystic Fibrosis Society",

year = "2020",

month = jan,

day = "27",

doi = "10.1016/j.jcf.2019.06.005",

language = "English",

volume = "19",

pages = "26--33",

journal = "Journal of Cystic Fibrosis",

issn = "1569-1993",

publisher = "Elsevier B.V.",

number = "1",

}

TY - JOUR

T1 - Do current clinical trials in cystic fibrosis match the priorities of patients and clinicans? A systematic review

AU - Kalaitzis, I. S.

AU - Rowbotham, N. J.

AU - Smith, S. J.

AU - Smyth, A. R.

N1 - Funding Information: NJR has given lectures at meetings sponsored by TEVA. AS has provided consultancy for Vertex and holds a current unrestricted research grant from Vertex. He has taken part in clinical trials sponsored by Vertex, Raptor and Insmed. He has given lectures at meetings sponsored by Teva and Vertex. Publisher Copyright: © 2019 European Cystic Fibrosis Society

PY - 2020/1/27

Y1 - 2020/1/27

N2 - There are many uncertainties regarding Cystic Fibrosis (CF) treatment. Recently, the first James Lind Alliance (JLA) Priority Setting Partnership (PSP) in CF was completed, bringing clinicians, patients and carers together to identify the Top 10 research priorities. Here we investigate how well the current clinical trials landscape reflects these priorities. Trials in CF were identified through searches of research databases (Pubmed, ANZCTR, EU clinical trials register, ClinicalTrials.gov and ISRCTN). Trials meeting inclusion criteria of registered intervention studies in CF published between 01.012016 and 11.09.2017 were matched to the Top 10 priorities. We identified 259 trials, with 193 fulfilling the inclusion criteria. Only 63 (33%) of these matched one or more of the JLA priorities showing that current clinical trials poorly reflect the JLA Top 10. By increasing awareness of the Top 10 priorities, it is hoped that this will fuel future research in areas important to the CF community.

AB - There are many uncertainties regarding Cystic Fibrosis (CF) treatment. Recently, the first James Lind Alliance (JLA) Priority Setting Partnership (PSP) in CF was completed, bringing clinicians, patients and carers together to identify the Top 10 research priorities. Here we investigate how well the current clinical trials landscape reflects these priorities. Trials in CF were identified through searches of research databases (Pubmed, ANZCTR, EU clinical trials register, ClinicalTrials.gov and ISRCTN). Trials meeting inclusion criteria of registered intervention studies in CF published between 01.012016 and 11.09.2017 were matched to the Top 10 priorities. We identified 259 trials, with 193 fulfilling the inclusion criteria. Only 63 (33%) of these matched one or more of the JLA priorities showing that current clinical trials poorly reflect the JLA Top 10. By increasing awareness of the Top 10 priorities, it is hoped that this will fuel future research in areas important to the CF community.

KW - Clinical trial

KW - Cystic fibrosis

KW - Research priority

U2 - 10.1016/j.jcf.2019.06.005

DO - 10.1016/j.jcf.2019.06.005

M3 - Article

C2 - 31235360

AN - SCOPUS:85067458519

SN - 1569-1993

VL - 19

SP - 26

EP - 33

JO - Journal of Cystic Fibrosis

JF - Journal of Cystic Fibrosis

IS - 1

ER -

Do current clinical trials in cystic fibrosis match the priorities of patients and clinicans? A systematic review

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this